These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17595817)

  • 1. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R; Kerner W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract]   [Full Text] [Related]  

  • 2. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current cost analysis in the management of diabetes mellitus].
    Oberender P
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 5. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-acting insulin analogues vs. human insulin for diabetes.
    Schooff M; Ehlers K
    Am Fam Physician; 2005 Sep; 72(5):805-7. PubMed ID: 16156336
    [No Abstract]   [Full Text] [Related]  

  • 7. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.
    Pollock RF; Valentine WJ; Pilgaard T; Nishimura H
    J Med Econ; 2011; 14(1):36-46. PubMed ID: 21192769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of patients with diabetes mellitus by means of inhaled insulin].
    Simsek S; de Galan BE; Tack CJ; Heine RJ
    Ned Tijdschr Geneeskd; 2006 Apr; 150(15):829-32. PubMed ID: 16676511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].
    Schröder J; Kerner W
    Dtsch Med Wochenschr; 2009 Nov; 134(46):2355; author reply 2355-6. PubMed ID: 19894207
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypoglycaemia, analogue insulins; prescribing cost or quality of life?
    Hitman GA
    Diabet Med; 2012 Mar; 29(3):289. PubMed ID: 22364579
    [No Abstract]   [Full Text] [Related]  

  • 11. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
    [No Abstract]   [Full Text] [Related]  

  • 12. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drugs for diabetes treatment. Fast-acting insulin analogues].
    Forst T
    Pharm Unserer Zeit; 2001; 30(2):118-23. PubMed ID: 11279981
    [No Abstract]   [Full Text] [Related]  

  • 15. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["The Lantus Case": What is the benefit of health economics?].
    Schöffski O
    Dtsch Med Wochenschr; 2010 May; 135(20):1033-5. PubMed ID: 20461663
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin therapy in type 2 diabetes: short-acting insulin analog has advantages].
    MMW Fortschr Med; 2006 Jun; 148(26):56-7. PubMed ID: 16875384
    [No Abstract]   [Full Text] [Related]  

  • 19. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes.
    Crasto W; Jarvis J; Khunti K; Davies MJ
    Postgrad Med J; 2009 May; 85(1003):257-67. PubMed ID: 19520878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits].
    MMW Fortschr Med; 2008 Dec; 150(49-50):56-7. PubMed ID: 19133372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.